Biomarker Changes in Samples From Young Patients With Acute Myeloid Leukemia
|ClinicalTrials.gov Identifier: NCT01139931|
Recruitment Status : Completed
First Posted : June 9, 2010
Last Update Posted : May 18, 2016
RATIONALE: Studying samples of blood or tumor tissue from patients with cancer in the laboratory may help doctors learn about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is studying biomarker changes in samples from young patients with acute myeloid leukemia.
|Condition or disease||Intervention/treatment|
|Leukemia||Genetic: DNA methylation analysis Genetic: gene expression analysis Genetic: microarray analysis Genetic: polymorphism analysis Other: laboratory biomarker analysis|
- Map key histone modifications and cytosine methylation in leukemia cell lines with defined oncogenic mutations.
- Acquire genome-wide maps of key histone modifications and cytosine methylation for primary leukemia in samples from patients with acute myeloid leukemia (AML).
- Investigate functional relationships between genetic and epigenetic landscapes in AML.
OUTLINE: Archived samples are analyzed in vivo and in vitro (cell line) for histone modification and cytosine methylation. Genome-wide locations of 5 histone modifications are analyzed using chip-Seq, as well as DNA methylation analysis at nucleotide-resolution by high-throughput bisulfite sequencing. These epigenetic data are correlated with genomic data (sequence analysis, expression array, SNP array).
|Study Type :||Observational|
|Estimated Enrollment :||15 participants|
|Official Title:||Epigenetic Alterations in AML|
|Study Start Date :||October 2009|
|Primary Completion Date :||May 2016|
- Relationships between genetic and epigenetic landscapes in AML
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01139931
|Principal Investigator:||Soheil Meshinchi, MD||Fred Hutchinson Cancer Research Center|